(a)
(b)
(c)
(d)
(e)
(f)
Figure 1: Lobeglitazone treatment improves systemic insulin resistance in high fat diet- (HFD-) fed mice. (a) The glucose tolerance test. Glucose (1 g/kg body weight) was intraperitoneally (i.p.) injected in overnight-fasted mice. (b) The insulin tolerance test. Blood glucose levels were measured at the indicated time points before and after i.p. injection of human regular insulin (0.75 U/kg) in mice fasted for 4 hours. (c) The fasting blood glucose level. (d) The fasting blood insulin level. (e) A homeostasis model for assessment of the insulin resistance index (HOMA-IR). (f) The gene expression levels of PEPCK and G6Pase related to gluconeogenesis were determined by qPCR in liver tissues. NU: normal chow diet- (NCD-) fed mice without treatment (NU, white circles and black bar), HU: HFD-fed mice without treatment (white squares and white bar), and HL: HFD-fed mice with lobeglitazone treatment (black triangles and gray bar). Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus HU group. #p < 0.05, ##p < 0.001, and ###p < 0.0001, HU versus. HL group.